Existing Account

Please login first to complete purchase/ quotation request, view custom order reports, or create favorites list.

Customer ID:
Stay Logged In

Forgot your Customer ID or Password?
New Account

Don't have an account with us yet? Please set up an account to place order or obtain customer services.

Antibodies  >  OptimAb Antibodies  >>  OptimAbᵀᴹ HA.11 , Monoclonal Antibody, AffinityMatrix

Product Name OptimAbᵀᴹ HA.11 , Monoclonal Antibody, AffinityMatrix
Clone: 16B12; Host: Mouse, Monoclonal Antibody
Size 500 g/250 L
Catalog # AFC-101P-500
US$ $306

The HA.11 antibody recognizes the influenza hemagglutinin (HA) epitope (YPYDVPDYA), corresponding to amino acids 98-106 of the human influenza hemagglutinin surface glycoprotein. This sequence has been used extensively as a general epitope tag in expression vectors. The extreme specificity of the antibody allows unambiguous identification and quantitative analysis of HA-tagged proteins. The HA.11 antibody recognizes HA epitopes located in the middle of protein sequences as well as at the N- or C-terminus.
This affinity matrix-bound Ab can be used for immunopurification of HA-tagged proteins.

Clone: 16B12
Isotype: IgG1,k
Reactivity: HA.11 Tag (YPYDVPDYA)
Immunogen: HA.11 was raised against the peptide CYPYDVPDYASL
Concentration:2 mg/mL
Formulation:PBS + 0.03% Thimerosal; The Ab was purified on Protein G and subsequently immobilized on SepharoseTM Fast Flow beads (Sepharose is a trademark of Amersham Biosciences Limited)
Applications:This immobilized Ab can be used for immunoprecipitation of HA-tagged proteins.
Working Dilutions:The Ab/protein binding can take place in common buffers (pH 6.0 - 7.5) in the presence of salt (50-500 mM) and reasonable levels of detergent. Excess amounts of reducing agent should be avoided as it would impact the disulfide bridges between the Ab heavy and light chains.

Detailed Information Datasheet
Storage 4C
References 1, Ferrando A et al. (2001) Nucl. Ac. Res. 29(17): 3685-3693.
2, Field J et al. (1988) Mol. Cell. Biol. 8: 2159-2165.
  < Back